RecruitingPhase 1NCT07002112
The LVIVO-TaVec100 Product in the Treatment of Relapsed/Refractory B-cell Malignancies
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of the LVIVO-TaVec100 Product in the Treatment of Relapsed/Refractory B-cell Malignancies
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Enrollment
30 participants
Start Date
May 23, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of the LVIVO-TaVec100 product in the Treatment of Relapsed/Refractory B-cell Malignancies.
Eligibility
Min Age: 18 YearsMax Age: 65 Years
Inclusion Criteria8
- Subjects voluntarily participate in clinical studies; Fully informed of this study and signed informed consent; Informed consent form must be obtained prior to initiation of any study-related tests or procedures that are not part of the standard treatment for the subject's disease; Good compliance and cooperation with follow-up.
- Aged 18-65 years (inclusive).
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- At least one evaluable tumor lesion.
- Relapsed and/or refractory NHL , and relapsed and/or refractory CLL with treatment indications
- Life expectancy≥ 3 months
- Clinical laboratory values meet screening visit criteria
- Adequate organ function;
Exclusion Criteria6
- Subject eligible for this study must not meet any of the following criteria:
- Prior antitumor therapy with insufficient washout period ;
- Prior treatment with other autologous cells or gene therapies other than targeting CD19 autologous CAR-T;
- Patients who are positive for hepatitis B surface antigen (HBsAg), hepatitis B virus core antibody (HBcAb), hepatitis B virus deoxyribonucleic acid (HBV DNA), hepatitis C antibody (HCV-Ab), hepatitis C virus ribonucleic acid (HCV RNA), and human immunodeficiency virus antibody (HIV-Ab).
- Known life-threatening allergic reaction, hypersensitivity reaction, or intolerance to study drug excipients and related excipients, including but not limited to DMSO; or those with a history of severe allergic reactions in the past (such as hypersensitivity reactions, or those with severe immune-related reactions such as the need for glucocorticoids to prevent anaphylaxis as assessed by the investigator).
- Lactating women;
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALLVIVO-TaVec100 product
Prior to infusion of the LVIVO-TaVec100 product, subjects will receive bridging therapy if needed.
Locations(6)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07002112
Related Trials
IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies
NCT073099001 location
Clinical Study Evaluating the Safety and Efficacy of BAFFR CAR-T Therapy for Relapsed/Refractory B-cell Malignancies
NCT073457281 location
Safety and Efficacy of ZZSW-01 in Relapsed/Refractory B-cell Malignancies
NCT072409741 location
UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies
NCT0659096111 locations
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
NCT057800349 locations